Our Opinion

Inhibrx Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“We performed a lung drug distribution study to measure the concentration of INBRX-101 and Prolastin-C in mice expressing human FcRn treated with either test article.” (Page 111) Read the full document

Company Description

Inhibrx, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of biologic therapeutic candidates. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological target.

Company Website: https://inhibrx.com